



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BAY-3827

Item No. 41448

CAS Registry No.: 2377576-35-5
Formal Name: N-[5-(3,5-dicyano-1,4-dihydro-1,2,6-trimethyl-4-pyridinyl)-6-fluoro-7-methyl-1H-indazol-3-yl]-2-ethyl-benzamide
MF: C₂₇H₂₅FN₆O
FW: 468.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAY-3827 is supplied as a solid. A stock solution may be made by dissolving the BAY-3827 in the solvent of choice, which should be purged with an inert gas. BAY-3827 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

BAY-3827 is an inhibitor of AMP-activated protein kinase (AMPK; IC₅₀ = 1.4 nM at 10 μM ATP).¹ It is selective for AMPK over Aurora A kinase, FMS-related tyrosine kinase 3 (FLT3), and c-Met (IC₅₀s = 1,324, 124, and 788 nM, respectively), p90 ribosomal S6 kinase 2 (RSK2), RSK3, RSK4, p90 ribosomal S6 kinase 1 (MSK1), and MST3 (IC₅₀s = 52, 36, 24, 43, and 94 nM, respectively), and a panel of 331 kinases at 10 μM but does inhibit RSK1 (IC₅₀ = 9 nM). BAY-3827 selectively inhibits the proliferation of androgen-dependent LNCaP, VCaP, and 22Rv1 prostate cancer cells (IC₅₀s = 0.28, 1.71, and 5.55 μM, respectively) over androgen receptor-negative C4-2B, PC3, and DU145 prostate cancer cells (IC₅₀s = >10 μM for all).

Reference

1. Lemos, C., Schulze, V.K., Baumgart, S.J., *et al.* The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models. *Cell. Oncol. (Dordr)* **44(3)**, 581-594 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/11/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM